Rituxan Add-On Curbs RA Joint Damage MedPage Today Adding the B-cell depleting agent rituximab (Rituxan) to methotrexate slowed joint damage progression in patients with rheumatoid arthritis (RA) regardless of the level of disease activity, Austrian researchers reported. At 1 year, patients with low ... |
